233 related articles for article (PubMed ID: 3882737)
61. Rapid regression of pituitary tumours during bromocriptine treatment of women with hyperprolactinaemia.
Bergh T; Nillius SJ; Lundberg PO; Moström U; Enoksson P; Ohman L; Wide L
Ups J Med Sci; 1982; 87(3):259-67. PubMed ID: 7157557
[TBL] [Abstract][Full Text] [Related]
62. [Results of bromocriptine treatment of giant or invasive prolactin adenomas. Apropos of 20 cases].
Scherrer H; Turpin G; De Gennes JL; Schaison-Cusin M; Heshmati HM; Thibierge M; Metzger J
Ann Med Interne (Paris); 1985; 136(6):459-66. PubMed ID: 4083636
[TBL] [Abstract][Full Text] [Related]
63. Macroprolactinomas and functionless pituitary tumours. Immunostaining and effect of dopamine agonist therapy.
Gasser RW; Mueller-Holzner E; Skrabal F; Finkenstedt G; Mayr U; Tabarelli M; Spoendlin H; Grunert V; Twerdy K
Acta Endocrinol (Copenh); 1987 Oct; 116(2):253-9. PubMed ID: 3116800
[TBL] [Abstract][Full Text] [Related]
64. Estrogen-induced prolactinoma in a man.
Gooren LJ; Assies J; Asscheman H; de Slegte R; van Kessel H
J Clin Endocrinol Metab; 1988 Feb; 66(2):444-6. PubMed ID: 3339116
[TBL] [Abstract][Full Text] [Related]
65. Serum prolactin and ovarian function after discontinuation of drug treatment for hyperprolactinaemia: a study with bromocriptine and metergoline.
Mattei AM; Ferrari C; Ragni G; Benco R; Picciotti MC; Rampini P; Caldara R; Crosignani PG
Br J Obstet Gynaecol; 1984 Mar; 91(3):244-50. PubMed ID: 6704349
[TBL] [Abstract][Full Text] [Related]
66. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
van der Lely AJ; Brownell J; Lamberts SW
J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
[TBL] [Abstract][Full Text] [Related]
67. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
Schettini G; Lombardi G; Merola B; Colao A; Miletto P; Caruso E; Lancranjan I
Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
[TBL] [Abstract][Full Text] [Related]
68. Effect of chronic bromocriptine administration on tumor size in patients with "nonsecreting" pituitary adenomas.
Verde G; Oppizzi G; Chiodini PG; Dallabonzana D; Luccarelli G; Liuzzi A
J Endocrinol Invest; 1985 Apr; 8(2):113-5. PubMed ID: 4031376
[TBL] [Abstract][Full Text] [Related]
69. Rapid decompression of anterior intracranial visual pathways with bromocriptine.
Grimson BS; Bowman ZL
Arch Ophthalmol; 1983 Apr; 101(4):604-6. PubMed ID: 6838419
[TBL] [Abstract][Full Text] [Related]
70. Normal growth and pubertal development during bromocriptine treatment for a prolactin-secreting pituitary macroadenoma.
Dalzell GW; Atkinson AB; Carson DJ; Sheridan B
Clin Endocrinol (Oxf); 1987 Feb; 26(2):169-72. PubMed ID: 3665115
[TBL] [Abstract][Full Text] [Related]
71. Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients.
Jamrozik SI; Bennet AP; James-Deidier A; Tremollieres F; Saint-Martin F; Dumoulin S; Valat-Coustols M; de Glisezinski I; Tremoulet M; Manelfe C; Louvet JP
J Endocrinol Invest; 1996; 19(7):472-9. PubMed ID: 8884542
[TBL] [Abstract][Full Text] [Related]
72. Short-term preoperative treatment of macroprolactinomas by dopamine agonists.
Fahlbusch R; Buchfelder M; Schrell U
J Neurosurg; 1987 Dec; 67(6):807-15. PubMed ID: 3681420
[TBL] [Abstract][Full Text] [Related]
73. Effects of bromocriptine for prolactin-secreting adenomas: analysis by CT scan.
Niwa J; Sato O; Tanabe S
Comput Radiol; 1983; 7(4):237-41. PubMed ID: 6641185
[TBL] [Abstract][Full Text] [Related]
74. Normal and abnormal prolactin levels during human pregnancy. Lack of influence on fetoplacental endocrine function.
Andersen AN; Pedersen H; Westergaard JG; Schiøler V; Arends J
Acta Obstet Gynecol Scand; 1984; 63(2):145-8. PubMed ID: 6730928
[TBL] [Abstract][Full Text] [Related]
75. Prolactin levels in pregnancy: comparison of normal subjects with patients having micro- or macroadenomas after early bromocriptine withdrawal.
Woodhouse NJ; Niles N; McDonald D; McCorkell S
Horm Res; 1985; 21(1):1-9. PubMed ID: 3972334
[TBL] [Abstract][Full Text] [Related]
76. Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia.
Ho KY; Smythe GA; Compton PJ; Lazarus L
Aust N Z J Med; 1985 Apr; 15(2):213-9. PubMed ID: 3927887
[TBL] [Abstract][Full Text] [Related]
77. Long-term medical therapy and follow-up of pediatric-adolescent patients with prolactin-secreting macroadenomas.
Blackwell RE; Younger JB
Fertil Steril; 1986 May; 45(5):713-6. PubMed ID: 3699173
[No Abstract] [Full Text] [Related]
78. Spontaneous sparsely-granulated prolactin-producing pituitary adenomas in aging rats. A prospective study of the effect of bromocriptine.
McComb DJ; Hellmann P; Kovacs K; Scott D; Evans WS; Burdman JA; Thorner MO
Neuroendocrinology; 1985 Sep; 41(3):201-11. PubMed ID: 4047338
[TBL] [Abstract][Full Text] [Related]
79. Size reduction of extrasellar pituitary tumors during bromocriptine treatment.
Wollesen F; Andersen T; Karle A
Ann Intern Med; 1982 Mar; 96(3):281-6. PubMed ID: 7059088
[TBL] [Abstract][Full Text] [Related]
80. [A case of male prolactinoma presenting extremely high serum prolactin levels and biphasic response to CB-154 suppression test].
Kabuto M; Hayashi M; Kawano H; Handa Y; Kobayashi H; Ishii H; Shirasaki N
No To Shinkei; 1985 Jun; 37(6):595-602. PubMed ID: 4041291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
